CN111954541A - 包含可溶性包封抗原的聚合物囊泡以及其制备方法和用途 - Google Patents

包含可溶性包封抗原的聚合物囊泡以及其制备方法和用途 Download PDF

Info

Publication number
CN111954541A
CN111954541A CN201980021354.5A CN201980021354A CN111954541A CN 111954541 A CN111954541 A CN 111954541A CN 201980021354 A CN201980021354 A CN 201980021354A CN 111954541 A CN111954541 A CN 111954541A
Authority
CN
China
Prior art keywords
seq
antigen
poly
polymersome
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980021354.5A
Other languages
English (en)
Chinese (zh)
Inventor
M·纳拉尼
F·德卡约
T·A·康奈尔
A·K·汗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acm Biological Laboratories Pte Ltd
Original Assignee
Acm Biological Laboratories Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acm Biological Laboratories Pte Ltd filed Critical Acm Biological Laboratories Pte Ltd
Publication of CN111954541A publication Critical patent/CN111954541A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980021354.5A 2018-01-25 2019-01-25 包含可溶性包封抗原的聚合物囊泡以及其制备方法和用途 Pending CN111954541A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18153348 2018-01-25
EP18153348.0 2018-01-25
PCT/EP2019/051853 WO2019145475A2 (en) 2018-01-25 2019-01-25 Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof

Publications (1)

Publication Number Publication Date
CN111954541A true CN111954541A (zh) 2020-11-17

Family

ID=61192649

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980021354.5A Pending CN111954541A (zh) 2018-01-25 2019-01-25 包含可溶性包封抗原的聚合物囊泡以及其制备方法和用途

Country Status (6)

Country Link
US (2) US12239736B2 (https=)
EP (1) EP3743101A2 (https=)
JP (2) JP7542257B2 (https=)
CN (1) CN111954541A (https=)
BR (1) BR112020013405A2 (https=)
WO (1) WO2019145475A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113416788A (zh) * 2021-07-14 2021-09-21 兰州大学 一种与湖羊睾丸性状相关的adpgk基因分子标记及其应用
CN120860194A (zh) * 2025-07-15 2025-10-31 中国人民解放军总医院第一医学中心 一种流感病毒纳米疫苗及其制备方法与应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201704135QA (en) * 2012-11-19 2017-06-29 Agency Science Tech & Res Method For Eliciting An Immune Response To An Immunogen
CN114502191B (zh) * 2019-08-01 2026-04-03 Acm生物实验室私人有限公司 通过施用具有关联的抗原的聚合物囊泡群和具有关联的佐剂的聚合物囊泡群来引发免疫应答的方法以及包含这两种聚合物囊泡群的组合物
US11642407B2 (en) 2020-02-28 2023-05-09 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
US20230256082A1 (en) * 2020-04-24 2023-08-17 Acm Biolabs Pte Ltd Vaccine against human-pathogenic coronaviruses
JP2024500360A (ja) * 2020-12-11 2024-01-09 エイシーエム バイオラブズ プライベート リミテッド 関連づけられた抗原および関連づけられたアジュバントを有する２つのポリマーソーム集団を投与することによる、Ｔｈ１／Ｔｈ２免疫応答の調整方法
CA3204785A1 (en) * 2021-02-02 2022-08-11 Madhavan Nallani Sole use of polymersome associated adjuvant for stimulating an immune response
WO2022218957A1 (en) * 2021-04-12 2022-10-20 Acm Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
WO2023183287A2 (en) * 2022-03-21 2023-09-28 The University Of North Carolina At Chapel Hill Composite bioactive compositions and applications thereof
WO2024081641A2 (en) * 2022-10-10 2024-04-18 Northwestern University Methods for preparing protein-conjugated nanocarriers
CN117045809B (zh) * 2023-09-27 2025-08-29 国家纳米科学中心 异种哺乳动物细胞来源的囊泡在制备疫苗载体中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1265038A (zh) * 1997-07-16 2000-08-30 法国国家卫生及研究医学协会 被称作胞外体的细胞囊泡,其制备方法及在免疫刺激中的用途
US20100255112A1 (en) * 2006-11-14 2010-10-07 The Trustees Of The University Of Pennsylvania Efficient Nuclear Delivery of Antisense Oligonucleotides or siRNA In Vitro and In Vivo by Nano-Transforming Polymersomes
WO2012018306A1 (en) * 2010-08-05 2012-02-09 Agency For Science, Technology And Research A multicompartmentalized vesicular structure and a method for forming the same
WO2014077781A1 (en) * 2012-11-19 2014-05-22 Agency For Science, Technology And Research Method for eliciting an immune response to an immunogen
US20140356415A1 (en) * 2013-06-03 2014-12-04 University Of Maryland, College Park Compositions and vaccines comprising vesicles and methods of using the same
WO2016055611A1 (en) * 2014-10-09 2016-04-14 Universität Basel Self-assembled nanostructures and methods of use thereof
WO2017151922A1 (en) * 2016-03-02 2017-09-08 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US569825A (en) 1896-10-20 John h
US633425A (en) 1899-01-26 1899-09-19 Louis Henry Clyborne Wire-tightener.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
DE602004025711D1 (de) 2003-08-21 2010-04-08 Lipotek Pty Ltd In vivo targeting von dendritischen zellen
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
CA2866170A1 (en) 2012-03-12 2013-09-19 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
EP2898894A1 (en) 2014-01-27 2015-07-29 LTS LOHMANN Therapie-Systeme AG Nano-in-micro particles for intradermal delivery
US9636397B2 (en) 2015-03-24 2017-05-02 VaxLiant, LLC Adjuvant compositions and related methods

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1265038A (zh) * 1997-07-16 2000-08-30 法国国家卫生及研究医学协会 被称作胞外体的细胞囊泡,其制备方法及在免疫刺激中的用途
US20100255112A1 (en) * 2006-11-14 2010-10-07 The Trustees Of The University Of Pennsylvania Efficient Nuclear Delivery of Antisense Oligonucleotides or siRNA In Vitro and In Vivo by Nano-Transforming Polymersomes
WO2012018306A1 (en) * 2010-08-05 2012-02-09 Agency For Science, Technology And Research A multicompartmentalized vesicular structure and a method for forming the same
WO2014077781A1 (en) * 2012-11-19 2014-05-22 Agency For Science, Technology And Research Method for eliciting an immune response to an immunogen
CN104936579A (zh) * 2012-11-19 2015-09-23 新加坡科技研究局 用于引发对免疫原的免疫响应的方法
US20140356415A1 (en) * 2013-06-03 2014-12-04 University Of Maryland, College Park Compositions and vaccines comprising vesicles and methods of using the same
WO2016055611A1 (en) * 2014-10-09 2016-04-14 Universität Basel Self-assembled nanostructures and methods of use thereof
WO2017151922A1 (en) * 2016-03-02 2017-09-08 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AMY SEXTON ET AL.: "A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules", 《ACS NANO》, vol. 3, no. 11, pages 3391 - 3400, XP055260712, DOI: 10.1021/nn900715g *
ARMANDO STANO ET AL.: "Tunable T cell immunity towards a protein antigen using polymersomes vs. solid-core nanoparticles", 《BIOMATERIALS》, vol. 34, no. 17, pages 4339 - 4346, XP029003916, DOI: 10.1016/j.biomaterials.2013.02.024 *
EVAN A SCOTT ET AL.: "Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes", 《BIOMATERIALS》, vol. 33, no. 26, pages 6213 *
HUANLI SUN ET AL.: "Reduction and pH dual-bioresponsive crosslinked polymersomes for efficient intracellular delivery of proteins and potent induction of cancer cell apoptosis", 《ACTA BIOMATER》, vol. 10, no. 5, pages 2159 - 2168 *
MARCELA RINCON-RESTREPO ET AL.: "Vaccine nanocarriers: Coupling intracellular pathways and cellular biodistribution to control CD4 vs CD8 T cell responses", 《BIOMATERIALS》, vol. 132, pages 48 - 58, XP029983981, DOI: 10.1016/j.biomaterials.2017.03.047 *
王晓艳: "多功能聚合物囊泡用于蛋白质的高效包裹及肝靶向的细胞内释放", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》, no. 2, pages 016 - 449 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113416788A (zh) * 2021-07-14 2021-09-21 兰州大学 一种与湖羊睾丸性状相关的adpgk基因分子标记及其应用
CN113416788B (zh) * 2021-07-14 2022-04-29 兰州大学 一种与湖羊睾丸性状相关的adpgk基因分子标记及其应用
CN120860194A (zh) * 2025-07-15 2025-10-31 中国人民解放军总医院第一医学中心 一种流感病毒纳米疫苗及其制备方法与应用

Also Published As

Publication number Publication date
US20210251899A1 (en) 2021-08-19
JP7542257B2 (ja) 2024-08-30
EP3743101A2 (en) 2020-12-02
BR112020013405A2 (pt) 2020-12-01
WO2019145475A3 (en) 2019-09-06
JP2024160341A (ja) 2024-11-13
US20250186346A1 (en) 2025-06-12
JP2021512142A (ja) 2021-05-13
WO2019145475A2 (en) 2019-08-01
US12239736B2 (en) 2025-03-04

Similar Documents

Publication Publication Date Title
US20250186346A1 (en) Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof
CN114502191B (zh) 通过施用具有关联的抗原的聚合物囊泡群和具有关联的佐剂的聚合物囊泡群来引发免疫应答的方法以及包含这两种聚合物囊泡群的组合物
CN104284680A (zh) 使用对受体的亲和力增加的突变型light分子用于癌症治疗的方法和组合物
JP2022552552A (ja) 活性薬剤または治療剤の送達のための水中油型エマルジョン製剤
US20250281405A1 (en) Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
CN112996539A (zh) 包含共价结合的抗原的聚合物囊泡以及其制备方法和用途
US20230398207A1 (en) Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
EP4288033B1 (en) Polymersome associated adjuvant for use in stimulating an immune response
CN119522232A (zh) 用于预防和治疗癌症的抗原肽
CA3197069A1 (en) Methods of treating diffuse large b-cell lymphoma
JP7086000B2 (ja) 体液性親和性の加速に関する方法及び組成物
WO2025257329A2 (en) Fusion polypeptide and liponanoparticle comprising the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20201117